Table 2.
Clinical parameters of 48 prostate cancer patients.
| Acronym | Age | Diagnosis | PSA value | Surgical resection | Outcome | Therapy | Mutated genes | Notes |
|---|---|---|---|---|---|---|---|---|
| B4536 | 62 | Prostate adenocarcinoma Gs 6 (3 + 3) | 0.41 | 2012 | Biochemical recurrence | Rescue radiation therapy | ATM, FOXA1 | None |
| B4972 | 66 | Prostate adenocarcinoma Gs 6 (3 + 3) | 0.02 | 2012 | No metastasis | None | KMT2D | Very low mutation frequency |
| B6393 | Deceased | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2012 | Deceased for oligodendroglioma no PCa metastasis | None | ATM, APC | Very low mutation frequency |
| B6998 | 70 | Prostate adenocarcinoma Gs 6 (3 + 3) and colon adenocarcinoma | Undetectable | 2012 | Abdominal lymph node metastasis | Chemotherapy | ZFHX3 | Very low mutation frequency |
| B3059 | 71 | Prostate adenocarcinoma Gs 6 (3 + 3) | NA | 2012 | Biochemical recurrence | Rescue radiation therapy | ATM, ZFHX3 | Very low mutation frequency |
| B1845 | 71 | Prostate adenocarcinoma Gs 6 (3 + 3) | NA | 2013 | No follow up | Unavailable data | none | No pathological mutations were detected |
| B992 | 80 | Prostate adenocarcinoma Gs 6 (3 + 3) and urothelial carcinoma | NA | 2013 | No follow up | Unavailable data | ATM, KMT2D, TP53 | ATM germline |
| B2726 | 75 | Prostate adenocarcinoma Gs 6 (3 + 3) and colon adenocarcinoma | 0.01 | 2013 | Biochemical recurrence | Rescue radiation therapy | KMT2D, SPOP | SPOP (hot spot) |
| B3082 | 77 | Prostate adenocarcinoma Gs 6 (3 + 3) | NA | 2013 | Biochemical recurrence | Rescue radiation therapy | FOXA1 | Very low mutation frequency |
| B2508 | 72 | Prostate adenocarcinoma Gs 6 (3 + 3) | NA | 2013 | No follow up | Unavailable data | none | No pathological mutations were detected |
| B501 | 73 | Prostate adenocarcinoma Gs 6 (3 + 3) | NA | 2011 | No follow up | Unavailable data | CHD1, APC, OR5L1, ATM, KMT2D, RB1, FOXA1, ZHFX3, SPOP, AR, MED12 | Multiple gene mutations |
| B8935 | 72 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | No metastasis | None | MED12, FOXA1 | Multiple mutations of FOXA1 gene |
| B1387 | 81 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | No metastasis | None | CHD1, COL5A1, KMT2D, ZFHX3, MED12, FOXA1 | Multiple gene mutations |
| B1753 | 68 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | No metastasis | None | ATM, KMT2D, ZFHX3, CDK12 | Very low mutation frequency |
| B1806 | 77 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | Biochemical recurrence | Rescue radiation therapy | ATM, KMT2D, FOXA1 | None |
| B8502 | 63 | Prostate adenocarcinoma Gs 6 (3 + 3) | NA | 2011 | No metastasis | None | APC, ATM, KTM2D, CDK12, FOXA1 | Multiple mutations of KTM2D |
| B6265 | 78 | Prostate adenocarcinoma Gs 6 (3 + 3) | NA | 2011 | No follow up | Unavailable data | KTM2D, FOXA1, ATM | None |
| B7149 | 85 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | No metastasis | None | none | No pathological mutations were detected |
| B7595 | 67 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | No metastasis | None | KMT2D | Very low mutation frequency |
| B7487 | 78 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | No metastasis | None | FOXA1 | None |
| B7756 | 75 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | No metastasis | None | none | No pathological mutations were detected |
| B7360 | 81 | Prostate adenocarcinoma Gs 6 (3 + 3) | Undetectable | 2011 | No metastasis | None | ATM, TP53, MED12 | None |
| B8752 | 78 | Prostate adenocarcinoma Gs 7 (3 + 4) | Undetectable | 2011 | No metastasis | Rescue radiation therapy | ATM | ATM germline |
| B8456 | 63 | Prostate adenocarcinoma Gs 7 (3 + 4) | NA | 2011 | No metastasis | None | none | No pathological mutations were detected |
| B778 | 80 | Prostate adenocarcinoma Gs 7 (3 + 4) | NA | 2011 | Biochemical recurrence | Rescue radiation therapy | ATM, FOXA1 | KMT2D germline |
| B8135 | 83 | Prostate adenocarcinoma Gs 7 (3 + 4) | NA | 2011 | No metastasis | None | PTEN, ATM | ATM germline |
| B7970 | 81 | Prostate adenocarcinoma Gs 7 (3 + 4) | Undetectable | 2011 | No metastasis | None | CDK12, AR, FOXA1 | Very low mutation frequency |
| B8234 | 74 | Prostate adenocarcinoma Gs 7 (3 + 4) | Undetectable | 2011 | Biochemical recurrence | Rescue radiation therapy | KMT2D, MED12, FOXA1 | None |
| B6286 | 73 | Prostate adenocarcinoma Gs 7 (3 + 4) | Undetectable | 2011 | Biochemical recurrence | Rescue radiation therapy | ATM, SPOP, FOXA1 | SPOP (hot spot) |
| B6547 | 78 | Prostate adenocarcinoma Gs 7 (3 + 4) | Undetectable | 2011 | Biochemical recurrence | Rescue radiation therapy | CHD1, ZFHX3, TP53, SPOP, FOXA1 | SPOP (hot spot) |
| B6607 | 78 | Prostate adenocarcinoma Gs 7 (3 + 4) | Undetectable | 2011 | Biochemical recurrence | Rescue radiation therapy | APC | Very low mutation frequency |
| B6055 | 69 | Prostate adenocarcinoma Gs 7 (3 + 4) | NA | 2011 | No follow up (alive) | Unavailable data | KMT2D, FOXA1 | None |
| B6395 | 79 | Prostate adenocarcinoma Gs 7 (3 + 4) | Undetectable | 2011 | No metastasis | None | KMT2D, FOXA1 | KMT2D germline |
| B6820 | 75 | Prostate adenocarcinoma Gs 7 (3 + 4) | NA | 2011 | No follow up (alive) | Unavailable data | PI3KCA, ZFHX3, PTEN | None |
| B6224 | 72 | Prostate adenocarcinoma Gs 8 (3 + 5), basocellular carcinoma and squamous cell carcinoma (skin) | NA | 2011 | Lymph node metastasis; total androgen blockade | LHRH analog | APC, KMT2D, ATM, FOXA1 | None |
| B8118 | 77 | Prostate adenocarcinoma Gs 8 (4 + 4) | NA | 2011 | Follow up until 2013 | Postsurgical radiotherapy and hormone therapy | MED12, FOXA1, RB1 | None |
| B8519 | 79 | Prostate adenocarcinoma Gs 8 (4 + 4) | NA | 2010 | No follow up (alive) | Unavailable data | COL5A1, ATM, KMT2D, FOXA1 | None |
| B5172 | 65 | Prostate adenocarcinoma Gs 8 (3 + 5) | NA | 2012 | No metastasis | Postsurgical radiotherapy and hormone therapy | ATM | Very low mutation frequency |
| B1658 | 77 | Prostate adenocarcinoma Gs 8 (3 + 5)and basocellular carcinoma | NA | 2013 | Biochemical recurrence | Rescue radiation therapy | ATM, SPOP | SPOP (hot spot) |
| B2325 | 71 | Prostate adenocarcinoma Gs 8 (4 + 4) | NA | 2013 | Lymph node metastasis | Unavailable data | ATM, SPOP, KTM2D, AR | SPOP (hot spot) |
| B779 | 77 | Prostate adenocarcinoma Gs 8 (5 + 3) | NA | 2013 | Bone metastasis; total androgen blockade | Vertebral radiotherapy | ATM | ATM germline |
| B2471 | 70 | Prostate adenocarcinoma Gs 8 (5 + 3) | NA | 2013 | Biochemical recurrence | Rescue radiation therapy | ATM, SPOP | ATM germline, SPOP (hot spot) |
| B3064 | 77 | Prostate adenocarcinoma Gs 8 (3 + 5) and squamous cell carcinoma (palate) | NA | 2013 | No metastasis | Postsurgical radiotherapy | FOXA1 | none |
| B6007 | 61 | Prostate adenocarcinoma Gs 8 (4 + 4) and b cell lymphoma cutaneous | NA | 2013 | No metastasis; total androgen blockade | Postsurgical radiotherapy | APC, ATM, KMT2D | Very low mutation frequency |
| B4441 | Deceased | Prostate adenocarcinoma Gs 8 (4 + 4) | NA | No surgery | Bone and visceral metastases | Bone radiotherapy, hormone therapy, Cabazitaxel | ATM, TP53 | TP53 germline |
| B435 | Deceased | Prostate adenocarcinoma Gs (5 + 4), urothelial carcinoma and squamous cell carcinoma (lung) | NA | 2013 | Lung cancer relapse | Chemotherapy for lung cancer | KMT2D | KMT2D germline |
| B2777 | 62 | Prostate adenocarcinoma Gs 8 (4 + 5) | NA | 2013 | Lymph node metastasis | Hormone therapy, radiotherapy | TP53 | None |
| B47 | Deceased | Prostate adenocarcinoma Gs (4 + 5), squamous cell carcinoma (larynx) and acinar lung adenocarcinoma | NA | 2014 | Lymph node metastasis | Hormone therapy, radiotherapy | TP53, CDK12 | CDK12 germline |
Note: Patient features, outcome, and putative causing‐disease mutated genes are indicated.
Abbreviations: NA, not available; PSA, prostate‐specific antigen.